What are the total costs of prescribing a particular drug? At its core, all health economics and outcomes research (HEOR) studies are designed to answer this fundamental question. And it is this answer that helps to remove barriers to market access. However, economic models are often cited as the least helpful aspect of dossiers that are provided to Managed Care.
Why? It’s simple – bias. In a recent survey conducted by Dymaxium via the AMCP eDossier system, presented at the May 2015 ISPOR Philadelphia Workshop session, “Making Better Use of Company Pharmacoeconomic Models”, the top reason for not using models provided by life sciences organizations is over concern with potential bias.
Historically, hard to calculate data points that power economic assessments, such as the costs of drug side effects, have come solely from manufacturers which because of their inherent conflict of interest, makes it fundamentally flawed. It is just smart marketing to ensure the numbers work out in favor of the manufacturer’s product. However, healthcare decision makers involved in reimbursement decisions are smart. They saw through attempts to spin data, and subsequently have paid little attention to HEOR that is sponsored by pharma. This however, did not negate their desire and need for unbiased HEOR data.
In order to fill this need and to correct for this bias, managed care has sought out independent data sources. Sources that rely on big data and real world evidence that have allowed for comparative effectiveness (including safety) research to take great leaps forward. The inherent bias and the availability of these independent, real world data, has pushed value assessment outside of the control of manufacturers and in turn, healthcare decision makers simply no longer have to rely on manufacturer controlled data.
In a world where the payer has more control over the success, and more importantly the failure, of manufacturers’ products, it is of vital importance to give the customer what they want. We’ve seen this first hand in our business at AdverseEvents. Upon launch in January 2014, pharma was less than thrilled with our disruption of the drug safety status quo. But as uptake at managed care organizations has grown, we are now seeing those same detractors looking for ways to use our data and analytics in their studies.
Why is standardized data, such as the costing of adverse events so valuable? Because making comparisons by class, indication, or mechanism of action are direct and plain. Methodologies are transparent and replicable. And most importantly healthcare decision makers can more quickly and accurately make important decisions.
In the case of a standardized adverse event costing metric such as RxCost®*, which calculates the average downstream medical cost from adverse events, it allows the user to track the economic results of emerging safety issues in new drugs, compare those to more established drugs, and even quickly formulate a financial model for novel developments like biosimiliars.
The ability to quickly obtain, easily review, and plug these data into cost effectiveness models, budget impact models and other supporting information for formulary decisions will dramatically improve patient outcomes and lower downstream medical costs. It’s that simple. And with an estimated $25 billion in avoidable serious events and negative patient outcomes from drug adverse events hitting the U.S. healthcare system in 2013, it seems the introduction of standardized costing methodologies, and other independent, real world evidence is right on time.
To learn more, download the RxCost white paper or contact us directly.
*RxCost® is part of the AdverseEvents Explorer platform that is being used by managed care organizations to ensure that healthcare decision makers have vital independent adverse event and outcomes costing data available during their drug purchasing and formulary management processes. This means they now have the tools to be proactive instead of reactive in their attempts to mitigate this enormous cost burden that adverse events have on their bottom lines.
Written by Jim Davis
As Executive Vice President, Jim manages the company’s global sales and business development efforts. Jim brings over 12 years of experience in commercial strategy, global sales management and execution, business development, and product development. He has over 9 years of specific domain expertise in biopharma market research, intelligence, and data.
– See more at: https://blogsitehealth.wpengine.com/#sthash.sRXMQ4hJ.dpuf